The Lancet Respiratory Medicine in conversation with

Treatment options in patients with systemic sclerosis-associated interstitial lung disease

January 05, 2021 The Lancet Respiratory Medicine
The Lancet Respiratory Medicine in conversation with
Treatment options in patients with systemic sclerosis-associated interstitial lung disease
Show Notes

Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.

Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv